Anraku, Tsutomu <br/><br/>
Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer.  [electronic resource] 

 -  International journal of molecular medicine  Feb 2020 
 - 315-323 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1791-244X 
<br/><br/><label>Standard No.: </label>10.3892/ijmm.2019.4427  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--chemistry<br/>Apoptosis--drug effects<br/>Cell Cycle Checkpoints--drug effects<br/>Cell Line, Tumor<br/>Glycogen Synthase Kinase 3 beta--antagonists & inhibitors<br/>Humans<br/>Kidney Neoplasms--drug therapy<br/>Maleimides--chemistry<br/>Protein Kinase Inhibitors--chemistry